Hanmi Pharm established a $730 million worth license contract for an anticancer new drug with Boehringer
Hanmi Pharm(President Kwan-soon Lee) announced on the 28th that it established a license contract for its targeted lung cancer new drug(HM61713), which is being developed on its own, with Boehringer Ingelheim.
Under the contract, Boehringer Ingelheim is now owning the right to exclusively sell H...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
